KSKiyoshi Shibuya

Kiyoshi Shibuya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kiyoshi Shibuya has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A case of stage I nasopharyngeal carcinoma combined with stage I small cell lung cancer detected with sputum cytology during lung cancer screening

    by Akemi Taguchi, Mitsutoshi Shiba, Hisami Kaneoya, Kiyoshi Shibuya, Yukio Nakatani, Takahiro Nakajima, Ichiro Yoshino, Takehiko Fujisawa

    背景 : 上咽頭癌は, 本邦では年間罹患数 500 例のまれな腫瘍で, 多くは進行癌で発見される. 肺小細胞癌も早期診断が困難で, 手術施行例はまれである. 喀痰検診によりⅠ期上咽頭癌が発見され, その精査中にⅠ期肺小細胞癌が診断された 1 例を経験したので報告する. 症例 : 68 歳, 男性, 喫煙指数 900. 喀痰検診 D 判定 (高度異型細胞) にて当施設を受診. 胸部 CT 検査は陰性で, 紹介病院での気管支鏡検査でも異常所見は認められなかった. 2 年後の喀痰集検が E 判定 (癌細胞) のため, 紹介病院にて内視鏡検査を再施行し, 生検組織診を行ったところ, Ⅰ期上咽頭癌が診断された. また胸部 CT 検査にて出現した肺小結節が経過観察中に増大したため, 胸腔鏡下右中葉切除術を施行した結果, Ⅰ期肺小細胞癌の診断が得られた. 細胞像ではライトグリーン好性の異型扁平上皮細胞および癌細胞が判定に有用であった. 結論 : 喀痰細胞診と胸部 CT 検査の併用による精査および経過観察は, 重複癌の早期発見に有用であった. 喀痰細胞診では黄色調のみならずライトグリーン好性の異型細胞にも留意する必要があった. 喀痰細胞診は発見が困難な頭頸部癌の早期発見に貢献できる可能性が示唆された.

  • In vivo microscopic imaging of the bronchial mucosa using an endo-cytoscopy system

    by Kiyoshi Shibuya, Taiki Fujiwara, Kazuhiro Yasufuku, Mohamed Alaa Rm, Masako Chiyo, Takahiro Nakajima, Hidehisa Hoshino, Kenzo Hiroshima, Yukio Nakatani, Ichiro Yoshino


  • Progress Toward Optical Biopsy: Bringing the Microscope to the Patient

    by Richard C. Newton, Samuel V. Kemp, Pallav L. Shah, Daniel Elson, Ara Darzi, Kiyoshi Shibuya, Stephen Mulgrew, Guang-Zhong Yang

    The investigation of many lung diseases currently requires bronchoscopic or surgical histopathological tissue biopsy. This creates risks for patients and entails processing costs and delays in diagnosis. However, several mainly probe-based biophotonic techniques that can image solitary lesions and diffuse lung diseases are fuelling a paradigm shift toward real-time in vivo diagnosis. Optical coherence tomography (OCT) uses near-infrared light in a process analogous to ultrasonography to image the mucosal and submucosal tissue boundaries of the bronchial tree. With 15-μm resolution, early work suggests it can differentiate between neoplasia, carcinoma in situ, dysplasia, and metaplasia based around epithelial thickness and breaches in the basement membrane. Probe-based confocal laser endomicroscopy (pCLE) has superior resolution but less penetration than OCT and employs blue argon laser light to fluoresce the endogenous elastin of (1) the acinar scaffold of the peripheral lung and (2) the basement membrane lying under bronchial mucosa. Initial studies suggest that the regular fibre arrangement of the basement membrane is altered in the presence of overlying malignant epithelium. pCLE produces detailed representations of the alveolar septal walls, microvessels, and some inflammatory cells. A third device, the endocytoscope, is a contact microscope requiring contrast agent to provide subcellular resolution of bronchial mucosa. Further development of these “optical biopsy” techniques and evaluation of diagnostic sensitivity and specificity of the acquired images are needed before they can be considered effective methods for eliminating the need for, and thus risks of, pinch biopsy to enable real-time diagnosis to streamline management.


  • Narrow band imaging with high-resolution bronchovideoscopy: A new approach for visualizing angiogenesis in squamous cell carcinoma of the lung

    by Kiyoshi Shibuya, Takahiro Nakajima, Taiki Fujiwara, Masako Chiyo, Hidehisa Hoshino, Yasumitsu Moriya, Makoto Suzuki, Kenzo Hiroshima, Yukio Nakatani, Ichiro Yoshino


  • Lymph Node Staging by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Patients With Small Cell Lung Cancer

    by Hironobu Wada, Takahiro Nakajima, Kazuhiro Yasufuku, Taiki Fujiwara, Shigetoshi Yoshida, Makoto Suzuki, Kiyoshi Shibuya, Kenzo Hiroshima, Yukio Nakatani, Ichiro Yoshino


  • Open Access

    Applicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers☆

    by Makoto Suzuki, Shigetoshi Yoshida, Hajime Tamura, Hironobu Wada, Yasumitsu Moriya, Hidehisa Hoshino, Kiyoshi Shibuya, Ichiro Yoshino

    Objective: A new staging system for lung cancer has been proposed by The International Association for the Study of Lung Cancer Staging Committee. We assessed the feasibility of this system for surgical patients. Methods: We reviewed the surgical outcome of 1623 consecutive patients with non-small-cell lung cancer (NSCLC), who underwent pulmonary resection in our institution, with regard to the subpopulations categorised in the current and proposed (2009) systems for postoperative pathologic staging. Results: The proportion of patients staged as IIA, IIB, IIIA and IV increased, while those staged as IB and IIIB decreased. Diseases staged as IIIA or earlier were significantly increased in the new system (current system: N = 1281, 78.9% vs new system: N = 1457, 89.8%). The 5-year survival rates of patients with new stages IB and IIA were clearly dissociated with 72.5% and 51.3%, respectively (P ≪ 0.0001). The 5-year survival rates of the newly classified T1 patients were 90.3% for T1aN0M0 and 81.5% for T1bN0M0 (P = 0.009). Re-classification of T2bN0M0 as stages IIA and T3 (same lobe nodules) N0M0 as stage IIB appropriately emphasised prognostic differences, while T4 (ipsilateral different lobe nodules) N2–3M0 (stage IIIB) and M1a (pleural effusion, stage IV) did not. Conclusions: This study demonstrated that the new system is superior to the current system in terms of the proportion and prognostic prediction of each stage, although it contains minor contradictions. Therefore, revision of the staging system will contribute to the decision for limited operation and adjuvant therapy of resected NSCLC.


  • P3-260: Chronic obstructive pulmonary disease decreases postoperative survival due to higher recurrence in male patients with stage IA lung cancer

    by Yasuo Sekine, Yoshito Yamada, Masako Chiyo, Takekazu Iwata, Kazuhiro Yasufuku, Akira Iyoda, Shigetoshi Yoshida, Makoto Suzuki, Kiyoshi Shibuya, Takehiko Fujisawa

  • Open Access

    Does perioperative high-dose prednisolone have clinical benefits for generalized myasthenia gravis?

    by Yasuo Sekine, Naoki Kawaguchi, Chikuma Hamada, Hiromi Sekiguchi, Kazuhiro Yasufuku, Akira Iyoda, Kiyoshi Shibuya, Takehiko Fujisawa

    Myasthenia gravis (MG) is an autoimmune disorder that results from dysfunction of the post-synaptic acetylcholine receptor (AchR), which may be due to reduced receptor density, increased turnover, or antibodies (AchR-Ab). Immunosuppressant therapies have been shown to suppress the destructive activity of AchR-Ab at neuromuscular junctions. Anticholinesterase inhibitors are used as a first-line medical therapy, and corticosteroids are used for patients with moderate to severe symptoms. However, anticholinesterase medications, such as pyridostigmine, do not prevent the AchR-Ab-mediated destruction of neuromuscular junctions. Furthermore, long-term use of anticholinesterases can reduce AchR responses due to the destruction of AchR, leading to increased anticholinesterase doses [1] that can suppress cardiac function [2].


  • Significance of Expression of Collagen XVIII as an Important Prognostic Factor in Non-Small Cell Lung Carcinoma

    by Toshihiko Iizasa, Hao Chang, Makoto Suzuki, Akira Iyoda, Kiyoshi Shibuya, Kenzo Hiroshima, Yukio Nakatani, Takehiko Fujisawa

    目的. XVIII型コラーゲンは, 血管新生抑制因子の一つであるエンドスタチンの前駆物質であり, 血管および上皮基底膜を構成する細胞外マトリックス蛋白の構成成分である. 本研究は非小細胞肺癌におけるXVIII型コラーゲン発現の予後因子としての重要性を明らかにすることを目的とした. 対象と方法. 1994~2000年に切除された非小細胞肺癌306例を対象とした. 男女比は215:91, 年齢は31~85歳 (平均64.8±9.8歳). 扁平上皮癌114例, 腺癌179例, 大細胞癌13例. 術後病期I期130例, II期47例, III期113例, IV期16例であった. 抗XVIII型コラーゲン抗体にて免疫染色を行い, 臨床的因子 (年齢, 性別, 組織型, T因子, N因子, 術後病期) との相関ならびに予後を統計学的に解析した. 結果. 抗XVIII型コラーゲン抗体による切除標本の染色結果は, 陰性92例, 陽性119例ならびに強陽性95例であった. 全体の5年生存率は陰性例70.4%, 陽性例56.5%ならびに強陽性例40.3%で, 強陽性群, 陽性群ではいずれも陰性例に比べ有意に予後不良であった (P<0.0001). 多変量解析でも, 免疫染色によるXVIII型コラーゲン発現は独立した予後因子として選択された. 結論. 非小細胞肺癌におけるXVIII型コラーゲンの発現は69.9%の症例に認められ, XVIII型コラーゲンの発現は予後を強く決定づける因子と考えられた.

    • 1 October 2004
      • Vol. 10  (5) , 293-6

    Dramatic improvement of respiratory condition after lobectomy for localized bullous emphysema.

    by Hironobu Wada, Yasuo Sekine, Shigetoshi Yoshida, Kazuhiro Yasufuku, Akira Iyoda, Toshihiko Iizasa, Yukio Saitoh, Takehiko Fujisawa, Kiyoshi Shibuya, Kenzo Hiroshima, et al.

    A case of dramatic improvement of respiratory function after lobectomy for bullous emphysema with severe hyperinflation of the left lower lobe was reported. A 72-year-old gentleman was admitted to our hospital due to increasing dyspnea with Hugh-Johns class V. His chest X-ray and computed tomography revealed a hyperinflation of the left lower lobe. Despite medication and respiratory rehabilitation, blood gas analysis showed hypercapnia and his symptoms had been progressing. Bronchofiberscopy revealed that the left lower lobe bronchi opened on inspiration and closed on expiration. Since complete destruction of the lower lobe due to air trapping was thought to be the cause of localized hyperinflation and the compression of left upper lobe, left lower lobectomy was performed. His dyspnea immediately disappeared and the respiratory function improved dramatically. We concluded that lobectomy could be considered as one of surgical options in case of complete lobar destruction in emphysema patients.